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a  b  s  t  r  a  c  t
Purpose:  To  evaluate  the  long-term  safety  and  seizure  outcome  in  Japanese  patients  with  Lennox–Gastaut
syndrome  (LGS)  receiving  adjunctive  ruﬁnamide  therapy.
Subjects  and  methods:  We  conducted  an  open-label  extension  study  following  a 12-week  multicenter,  ran-
domized, double-blind,  placebo-controlled  study  of  adjunctive  ruﬁnamide  therapy  in Japanese  patients
with LGS.  Fifty-four  patients  participated  in  the  extension  study.  Seizure  frequency  was  evaluated  until
52 weeks  after  the start  of  the  extension  study.  Adverse  events  (AEs)  were  evaluated  throughout  both
studies.
Key  ﬁndings:  Of  the  54  patients,  41 (75.9%)  completed  the extension  study.  The  median  duration  of  expo-
sure  to ruﬁnamide  was  818.0  days  in  all 54  patients,  and  38  patients  (70.4%)  received  ruﬁnamide  for
2  years  or  more.  The  median  percent  change  in the frequency  of tonic–atonic  seizures  relative  to  the
frequency  at  the  start  of  the  double-blind  study  was  −39.3%  (12 weeks),  −40.6% (24 weeks),  −46.8%  (32
weeks),  −47.6%  (40  weeks),  and  −36.1%  (52 weeks).  Reduction  of  total  seizure  frequency  was  also  main-
tained  until  52  weeks.  Frequent  treatment-related  AEs  were  somnolence  (20.4%),  decreased  appetite
(16.7%),  transient  seizure  aggravation  including  status  epilepticus  (13.0%),  vomiting  (11.1%),  and  consti-
pation (11.1%).  Adverse  events  were  mild  or moderate,  except  for transient  seizure  aggravation  in three
patients. Adverse  events  resulting  in discontinuation  of  ruﬁnamide  were  decreased  appetite,  drug  erup-
tion,  and  worsening  of  underlying  autism.  When  clinically  notable  weight  loss  was  deﬁned  as  a  decrease
≥7%  relative  to  baseline,  22  patients  (40.7%)  experienced  weight  loss  at  least  once during  long-term
observation,  although  weight  loss  was  reported  as an  AE in only  three  patients.
Signiﬁcance:  This  study  demonstrated  a  long-term  beneﬁt  of ruﬁnamide  as adjunctive  therapy  for
Japanese  patients  with  LGS.  Exacerbation  of  seizures  and  decreased  appetite/weight  loss should  be
monitored  carefully.
ublis©  2016  The  Authors.  P∗ Corresponding author. Current address: Asahigawaso Rehabilitation and Medi-
al Center, 855 Gion Kita-ku, Okayama 703-8555, Japan.
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1. Introduction
Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy
characterized by various types of epileptic seizures (mainly tonic
seizures), diffuse slow spike-and-wave complex patterns on the
electroencephalogram (EEG), and impairment of cognitive func-
tion. The long-term prognosis for mental function and seizures
is generally devastating (Arzimanoglou et al., 2009; Beaumanoir,
1985; Blatter-Ariﬁ, 1991; Oguni et al., 1996; Ohtsuka et al., 1990;
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agi, 1996). A high risk of sudden falls due to tonic and/or atonic
eizures often affects the quality of life.
Ruﬁnamide is a triazole derivative with a different structure
o other antiepileptic drugs (AEDs). It has been found that ruﬁ-
amide modulates the frequency of sodium-dependent neuronal
ction potentials in cultured spinal cord neurons (McLean et al.,
005). In addition, recent basic research using recombinant tech-
ology demonstrated that the primary target of ruﬁnamide in the
uman brain seems to be a particular isoform of the voltage-gated
odium channel (Nav1.1) (Gilchrist et al., 2014). The effectiveness
f ruﬁnamide as adjunctive therapy for LGS was established by a
ouble-blind, randomized, placebo-controlled study (Glauser et al.,
008) and also by our recent study in Japanese patients (Ohtsuka
t al., 2014).
Our recent study demonstrated that adjunctive therapy with
uﬁnamide signiﬁcantly reduced the frequency of tonic–atonic
eizures by 24.2% compared with 3.3% in the placebo group
p = 0.003), and also reduced total seizure frequency by 32.9% com-
ared with 3.1% in the placebo group (p < 0.001). The ruﬁnamide
roup showed a signiﬁcantly higher responder rate of tonic–atonic
eizures than the placebo group and ruﬁnamide treatment was
enerally well tolerated, with decreased appetite, somnolence,
nd vomiting being the most frequent treatment-related adverse
vents (AEs). Here we report the results of an open-label extension
tudy that was performed after the above-mentioned double-blind
tudy.
. Subjects and methods
.1. Study design
This was an open-label extension study following a 12-week
ulticenter, randomized, double-blind, placebo-controlled study
f adjunctive ruﬁnamide therapy in Japanese patients with LGS
Ohtsuka et al., 2014). In the preceding placebo-controlled study,
ligible patients were aged 4–30 years and weighed 15 kg or more
t baseline. Lennox–Gastaut syndrome was diagnosed from a his-
ory of tonic and/or atonic seizures and atypical absence seizures
ith slow spike-and-wave complex patterns on the EEG within 6
onths before the baseline period. Eligible patients had experi-
nced at least 90 seizures during the 28 days before the baseline
eriod, and were taking between one and three AEDs. Patients were
xcluded from the study if tonic–clonic status epilepticus occurred
uring the baseline period. Patients were also excluded if they had
ther severe medical conditions or electrocardiographic/laboratory
bnormalities.
This extension study consisted of three periods: a pre-
onversion period (maximum of four weeks for ﬁxation of data
rom the preceding double-blind study), a conversion period, and
 maintenance period. During the conversion period, placebo was
radually replaced by ruﬁnamide within two weeks under double-
lind conditions. The maintenance period of the study continued
ntil ruﬁnamide was released in Japan (May 2013). Fifty-four
atients participated in the extension study. Hospital visits were
cheduled at 4, 8, 12, 18, 24, 32, and 40 weeks, then every 12 weeks
s the extension study continued. The primary objective of the
xtension study was to evaluate the long-term safety of adjunctive
herapy with ruﬁnamide, and the secondary objective was  to eval-
ate seizure outcomes with this therapy. Therefore, we assessed
afety variables at all hospital visits throughout the extension study
n all 54 patients, as well as during the double-blind placebo-
ontrolled study. On the other hand, the efﬁcacy variable (seizure
requency) was only assessed at 12, 24, 32, 40, and 52 weeks.
atients who discontinued the extension study before the 12-week
oint were excluded from the analysis of seizure outcomes.search 121 (2016) 1–7
Ruﬁnamide was  administered twice a day and the daily dose
was determined individually based on body weight. Dose reduc-
tion by one level (approximately 25% according to dose titration
schedule in the preceding placebo-controlled study) was allowed
if the investigator judged that it was  necessary for safety (Ohtsuka
et al., 2014). The number and types of concomitant AEDs could be
changed during the extension study, but administration of more
than three concomitant AEDs with ruﬁnamide was  not allowed.
Rescue treatment (e.g. intravenous or rectal diazepam) was also
permitted for transient seizure aggravation including status epilep-
ticus.
Seizure frequency was determined from a diary recorded by the
caregivers (mainly parents, but also including schoolteachers and
childcare workers). During the extension study, caregivers were
instructed to record data in the seizure diary for the 7-day period
after each designated hospital visit (12, 24, 32, 40, and 52 weeks).
This was done to reduce the burden on caregivers while still evalu-
ating the change in seizure frequency consistently throughout the
extension study. Seizures were classiﬁed according to the Inter-
national League Against Epilepsy (ILAE) Classiﬁcation of Epileptic
Seizures (Commission on Classiﬁcation and Terminology of the
ILAE, 1981). Amelioration of tonic seizures and/or atonic seizures
is essential for LGS patients, since these seizures often result in
sudden falls and disturb the patients’ quality of life. Referring to
the previous study (Glauser et al., 2008), the sum of frequencies of
tonic seizures and atonic seizures was deﬁned as the frequency of
tonic–atonic seizures. The percent change of seizure frequency was
calculated as [(M − B)/B] × 100, where M was  the seizure frequency
during the maintenance period of the extension study and B was
the seizure frequency during the baseline period of the preceding
placebo-controlled study. The 50% responder rate was calculated
as the percentage of patients with at least 50% reduction in the
frequency of seizures.
In all 54 patients who  participated in the extension study, AEs
were evaluated throughout the entire ruﬁnamide treatment period,
including the preceding placebo-controlled study. Adverse events
were assessed by an investigator at each visit and the investiga-
tor also classiﬁed the severity of each AE as mild (tolerable and
not interfering with daily activities), moderate (interfering with
daily activities) or severe (severely disabling). The relationship of
each AE with ruﬁnamide was categorized by the investigator as
“not related”, “possibly related”, or “probably related”. Treatment-
related AEs were deﬁned as “possibly related” or “probably related”
AEs. In addition, clinical laboratory tests, body weight, and the elec-
trocardiogram (ECG) were evaluated.
This study was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice for trials of medical products
and was approved by the ethical committee of each participating
hospital. Written informed consent was obtained from the legal
guardians and/or the patients prior to participation in the extension
study.
2.2. Statistical methods
Because this was an open-label extension study, descriptive
statistics were calculated for continuous variables and categorical
variables. The percentage, median, mean, and standard deviation
were calculated for the demographic proﬁle, seizure outcomes, and
safety variables. Patients with no seizure data were excluded from
the analysis of seizure outcome.
In children aged ≤15 years, the absolute body weight was  mea-
sured and it was also calculated as a ratio relative to the average
weight for Japanese children according to Japanese government
statistics (Kato et al., 2014; Ministry of Education, Culture, Sports,
Science and Technology, 2012) to allow for the inﬂuence of devel-
opmental weight gain.






































Demographic and baseline characteristics of the 54 patients in the extension study.
Male, n (%) 33 (61.1)
Mean age (SD), years 15.0 (6.8)
Mean weight (SD), kg 39.8 (18.5)
Mean time after diagnosis of LGS (SD), years 10.0 (6.5)
Underlying cause, n (%) 25 (46.3)
Seizure type, n (%)
Multiple seizure types 40 (74.1)
Tonic–atonic seizures only 14 (25.9)
Tonic–atonic seizure frequency,a median (range) 227.1 (8.3–22,469.5)
Total seizure frequency,a median (range) 274.0 (63.0–22,499.4)




Concomitant AEDs,b n (%)






LGS, Lennox–Gastaut syndrome; AED, antiepileptic drug.Y. Ohtsuka et al. / Epile
Electrocardiographic data were obtained digitally and ECG
arameters were calculated automatically. The QT interval was
orrected for heart rate (QTc) according to Bazett’s formula: QT
nterval*(60/heart rate)1/2.




All 54 patients who completed the preceding placebo-controlled
tudy participated in this extension study (Fig. 1). Forty-one (75.9%)
atients completed the extension study and 13 patients (24.1%)
iscontinued ruﬁnamide treatment. The reasons for discontinua-
ion of ruﬁnamide were lack of efﬁcacy (13.0%), AEs (7.4%), and
ther reasons (3.7%). Seizure outcomes were evaluated in 46 of the
4 patients. The median duration of exposure to ruﬁnamide was
18.0 days (range: 13.5–1042.5 days) in all 54 patients, while it
as 859.5 days (range: 164.0–1042.5 days) in the 46 patients eval-
ated for seizures. Thirty-eight patients (70.4%) received treatment
ith ruﬁnamide for at least 2 years.
The mean daily dosage [mean ± standard deviation (SD)] was
0.7 ± 6.8 mg/kg, while the daily dosage stratiﬁed by body weight
as as follows: 989.9 ± 43.1 mg  (15.0–30.0 kg), 1607.3 ± 261.8 mg
30.1–50.0 kg), 2306.8 ± 198.6 mg  (50.1–70.0 kg), and
042.6 ± 266.1 mg  (≥70.1 kg).
In the safety analysis set, consisting of all 54 patients in the
xtension study, the mean baseline age of the patients [mean ± SD]
as 15.0 ± 6.8 years (Table 1). Twenty-two patients (40.7%) were
ged 4–11 years, 11 (20.4%) were aged 12–16 years, and 21 (38.9%)
ere ≥17 years old. The common underlying causes were tuber-
us sclerosis and cerebral palsy (ﬁve patients each), followed by
erebral dysgenesis, encephalitis, and bacterial meningitis (three
atients each).
Patients were taking one (3 patients, 5.6%), two (12 patients,
2.2%) or three (39 patients, 72.2%) concomitant AEDs at the start of
he extension study and also at baseline. Concomitant AEDs used by
10% of the patients at the start of the extension study were valproic
cid (49 patients, 90.7%), lamotrigine (34 patients, 63.0%), clobazam
16 patients, 29.6%), phenytoin (12 patients, 22.2%), carbamazepine
8 patients, 14.8%), and clonazepam (7 patients, 13.0%) as shown in
able 1. Forty-one patients (75.9%) continued the same concomi-
ant AEDs throughout the extension study. In the 46 patients whose
eizure outcomes were evaluated, the changes of the concomitant
Fig. 1. Disposition oa Seizure frequency per 28 days.
b Concomitant AEDs used by at least 10% of patients at the start of the extension
study.
AEDs by 52 weeks after the start of the extension study were as
follows: addition of one AED in four patients, switching of AEDs
without changing the number of concomitant AEDs in four patients,
and deletion of one AED in ﬁve patients. Other treatments, such as
vagus nerve stimulation or a ketogenic diet, were not performed
in any of the patients. Reduction of the dose of ruﬁnamide by one
level was  done in six patients during the extension study.
3.2. Seizure outcome
Eight of the 54 patients were excluded from the analysis of
seizure outcomes due to lack of seizure data because of early dis-
continuation before the 12-week point of the extension study.
Seizure outcomes were evaluated in the remaining 46 patients. The
median percent change in the frequency of tonic–atonic seizures
relative to baseline was −39.3% at 12 weeks, −40.6% at 24 weeks,
−46.8% at 32 weeks, −47.6% at 40 weeks, and −36.1% at 52 weeks
(Fig. 2). The median percent change of total seizure frequency rel-
ative to baseline was −47.7% at 12 weeks, −48.9% at 24 weeks,
−50.6% at 32 weeks, −52.0% at 40 weeks, and −47.4% at 52 weeks. At
the last observation, 43.5% of the patients showed ≥50% reduction
f the patients.
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Aeizure frequency relative to baseline during the extension study. *One patient was
xcluded from analysis of total seizure frequency at 12 weeks because the number
f  myoclonic seizures was  not recorded in the seizure diary.
f total seizure frequency, including 39.1% of patients with ≥50%
eduction of tonic–atonic seizures and 37.5–85.7% of patients with
50% reduction of other types of seizures (Table 2). One patient
2.2%) was completely free from seizures at the last observation,
hereas ﬁve patients (10.9%) showed a ≥25% increase of total
eizure frequency relative to baseline.
.3. SafetyAdverse events occurred in all 54 patients and treatment-related
Es occurred in 38 patients (70.4%) during the entire study period,
ncluding the preceding placebo-controlled study (Table 3). The
able 2
umbers of patients with 100% reduction, ≥50% reduction, and ≥25% increase of seizure 
Seizure type na 100% reduc
Tonic–atonic seizures 46 4 (8.7) 
Tonic  seizures 45 4 (8.9) 
Atonic  seizures 16 6 (37.5) 
Atypical absence seizures 24 13 (54.2) 
Myoclonic seizures 14 8 (57.1) 
Tonic–clonic seizures 8 2 (25.0) 
Partial  seizures 7 3 (42.9) 
Total  seizures 46 1 (2.2) 
umber of patients (%).
a Number of patients with a given type of seizure during the baseline period.
able 3
ommon adverse events and treatment-related adverse events.
AEs, n (%) Treatment-rel
All events 54 (100.0) 38 (70.4) 
Nasopharyngitis 29 (53.7) 1 (1.9) 
Transient seizure aggravation 23 (42.6) 7 (13.0) 
Somnolence 18 (33.3) 11 (20.4) 
Vomiting 15 (27.8) 6 (11.1) 
Inﬂuenza 12 (22.2) 0 
Contusion 12 (22.2) 0 
Decreased appetite 11 (20.4) 9 (16.7) 
Constipation 9 (16.7) 6 (11.1) 
Dental caries 9 (16.7) 0 
Upper respiratory tract infection 8 (14.8) 0 
Stomatitis 6 (11.1) 2 (3.7) 
Pyrexia 6 (11.1) 0 
Bronchitis 6 (11.1) 0 
Insomnia 6 (11.1) 2 (3.7) 
Epistaxis 6 (11.1) 1 (1.9) 
E, adverse event.search 121 (2016) 1–7
common treatment-related AEs were somnolence (11 patients,
20.4%), decreased appetite (9 patients, 16.7%), transient seizure
aggravation including status epilepticus (7 patients, 13.0%), and
vomiting and constipation (6 patients each, 11.1%).
All AEs were mild or moderate, except for transient seizure
aggravation in three patients. A 19-year-old woman experienced
exacerbation of tonic seizures on Day 717 of ruﬁnamide admin-
istration, and was admitted to hospital. Her symptoms gradually
resolved after she received intravenous phenytoin and she returned
to the previous state by 17 days after the onset. In addition, a
12-year-old boy developed nonconvulsive status epilepticus on
Day 207 of ruﬁnamide administration. By adjusting the doses of
concomitant AEDs (increasing valproate and decreasing phenobar-
bital), his nonconvulsive status epilepticus resolved after 17 days.
The third patient was a 15-year-old girl who developed nonconvul-
sive status epilepticus on Day 434 of ruﬁnamide administration. It
resolved soon after administration of a diazepam suppository. The
ﬁrst two patients had not experienced the same type of seizure
exacerbation before participating in this study. In all three patients,
exacerbation was  evaluated as a treatment-related AE. In this study,
investigators performed comprehensive assessment of the severity
and frequency of seizures before deciding whether seizure exacer-
bation was a treatment-related AE.
Adverse events resulted in discontinuation of ruﬁnamide in four
patients, with the events being decreased appetite in two  patients
(3.7%), drug eruption in one patient (1.9%), and worsening of under-
lying autism in one patient (1.9%). All of these events resolved
without sequelae after discontinuation of ruﬁnamide.
Decreased appetite is one of the characteristic AEs associated
with ruﬁnamide. Its incidence was higher in patients aged ≥17
years than in the other age groups [1/22 patients (4.5%) aged 4–11
frequency at ﬁnal observation.
tion ≥50% reduction ≥25% increase
18 (39.1) 5 (10.9)
18 (40.0) 6 (13.3)
11 (68.8) 2 (12.5)
18 (75.0) 2 (8.3)
9 (64.3) 2 (14.3)
3 (37.5) 1 (12.5)
6 (85.7) 1 (14.3)
20 (43.5) 5 (10.9)














































































Fig. 3. Mean percent changes of body weight in patients with (red) or without
(blue) decreased appetite during the extension study. (A) Patients aged 4–11 years;
(B) patients aged 12–16 years; (C) patients aged 17 years or older; (%), number ofY. Ohtsuka et al. / Epile
ears, 2/11 (18.2%) patients aged 12–16 years, and 8/21 (38.1%)
atients ≥17 years old]. When we deﬁned clinically notable weight
oss as a decrease of weight by ≥7% relative to baseline, it occurred
n 22 (40.7%) patients at least once during the observation period.
owever, weight loss was judged to be an AE by the investiga-
ors in only 3 patients (a 5-year-old boy, a 16-year-old girl, and a
0-year-old woman). In this study, the investigators did not have
 quantitative deﬁnition to guide them when deciding whether
eight loss was an AE. The mean percent change of body weight
rom baseline in each age category is presented in Fig. 3. In patients
ged ≥17 years, decreased appetite and weight loss tended to be
ssociated with longer exposure to ruﬁnamide. In patients aged
15 years, the weight ratio (mean ± SD) relative to the average
eight of healthy Japanese children was 0.86 ± 0.22 at baseline,
hile it was 0.75 ± 0.19 after 1 year, 0.74 ± 0.17 after 2 years, and
.75 ± 0.13 after 3 years of exposure to ruﬁnamide. There were no
ifferences between boys and girls.
Electrocardiographic ﬁndings reported as treatment-related
Es were ventricular arrhythmia, sinus arrhythmia, and QT pro-
ongation in one patient (1.9%) each. All of these changes were mild
nd were not seen on subsequent ECGs without discontinuation of
uﬁnamide. There were no differences of ECG parameters between
aseline and ﬁnal observation. In particular, QTc (mean ± SD) was
12.2 ± 27.5 ms  at baseline and 407.4 ± 24.6 ms  at ﬁnal observation,
ith the mean change of QTc from baseline being−4.8 ± 32.2 ms.
All of the abnormal clinical laboratory test results reported as
reatment-related AEs only occurred in one patient each.
. Discussion
This extension study demonstrated that ruﬁnamide maintained
eizure control over the long term and that there was a relatively
igh retention rate of ruﬁnamide therapy beyond 2 years. In the
resent study, we adopted intermittent assessment (seven days
fter each outpatient visit) to evaluate the changes of seizure fre-
uency while reducing the burden on caregivers. This method of
ssessment might potentially be less accurate compared with the
receding double-blind study during which seizure diaries were
ecorded for the entire study period. However, we were able to
onﬁrm that efﬁcacy of ruﬁnamide was maintained throughout
he extension study without large ﬂuctuations and the long-term
eizure outcome in the present study was compatible with the
esults of other long-term studies on ruﬁnamide (Kluger et al.,
010a,b; Coppola et al., 2010; Kim et al., 2012; Thome-Souza et al.,
014; Kessler et al., 2015). In addition, the high retention rate in the
resent study indicates that this drug has a favorable risk/beneﬁt
alance for Japanese patients with LGS. It was recently suggested
hat the mechanism of drug resistance in some types of epilepsy
including LGS) involves over-expression of P-glycoprotein in the
ndothelium of the blood–brain barrier (Zhang et al., 2012; Kumar
t al., 2014). It is thought that penetration of the blood–brain bar-
ier by ruﬁnamide is not affected because it is not a substrate of
uman P-glycoprotein (Chan et al., 2014), and this pharmacologi-
al characteristic may  be related to its long-term effectiveness for
GS.
During the present long-term study, the safety proﬁle of
uﬁnamide was similar to that revealed by the preceding placebo-
ontrolled study (Ohtsuka et al., 2014) and we did not ﬁnd any new
ate-onset AEs. A recent review of ruﬁnamide also suggested that
his drug has a favorable risk/beneﬁt proﬁle with a low risk of exac-
rbating seizures (Coppola et al., 2009). While it is known that some
EDs may  cause worsening of seizures, the precise mechanisms
nderlying this paradoxical effect have not been clariﬁed (Gayatri
nd Livingston, 2006). According to the National Institute for Health
nd Care Excellence (NICE) guideline, carbamazepine, gabapentin,patients; M, month. Error bars represent SD.
oxcarbazepine, pregabalin, tiagabine, and vigabatrin are not recom-
mended for patients with LGS due to the possibility of exacerbating
seizures (Nunes et al., 2012). Transient seizure aggravation was
one of the common treatment-related AEs in our study and there
were some severe events, suggesting that patients should be closely
monitored for changes in the frequency and severity of seizures
during administration of ruﬁnamide, although transient exacerba-
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Regarding weight loss, it is notable that 40.7% of patients
howed weight loss (≥7% decrease relative to baseline) in our study,
lthough it was not severe in most cases. We  also saw a tendency for
hildren taking ruﬁnamide to not show appropriate developmental
eight gain with increasing age. Therefore, it seems to be impor-
ant to carefully monitor body weight during long-term ruﬁnamide
herapy and adjust the dosage if necessary. It is known that topi-
amate, zonisamide, and felbamate, which are often used for the
reatment of LGS, can induce weight loss (Ben-Menachem, 2007).
ccordingly, combined use of these AEDs with ruﬁnamide would
equire caution.
In healthy volunteers, ruﬁnamide induced a dose-related
ecrease of QTc by approximately 20 ms.  QT shortening may
ncrease the risk of sudden death and ventricular arrhythmias, and
linically relevant shortening of QTc has been deﬁned as reduc-
ion of 80 ms  from baseline and/or a QTc duration of 320 ms  or
ess (Shah, 2010). In the present study, QTc only showed a slight
ecrease (−4.8 ± 32.2 ms), which seems unlikely to be clinically rel-
vant, and few ECG ﬁndings were reported as treatment-related
Es. These results indicate that there is no signiﬁcant cardiovascu-
ar risk associated with long-term administration of ruﬁnamide.
There is still a lack of sufﬁcient evidence about the efﬁcacy
nd safety of ruﬁnamide. While the present study provided useful
upporting evidence regarding the favorable proﬁle of ruﬁnamide,
he results must be interpreted with caution due to its open-label
esign and lack of a control group. The other main limitation of this
tudy was that the number of patients was too small to analyze
he characteristics of subgroups such as responders, patients with
ransient seizure aggravation, and patients with weight loss and/or
ecreased appetite. Lastly, the intermittent assessment procedure
dopted in this extension study might not have provided sufﬁcient
ata to evaluate seizure control. Accordingly, larger-scale clinical
rials will be needed to clarify the speciﬁc clinical factors related to
aintenance of seizure control and the safety of ruﬁnamide.
. Conclusion
We  performed an open-label extension study to evaluate the
ong-term safety and seizure outcome in Japanese patients with
GS receiving adjunctive ruﬁnamide therapy. Reduction of total
eizure frequency, including tonic–atonic seizures, was maintained
p to 52 weeks and 75.9% of patients completed the extension
tudy. Most AEs associated with ruﬁnamide therapy were mild
r moderate, although exacerbation of seizures and decreased
ppetite/weight loss require attention.
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